Evidence map›Paper›PMID 36443499›Full record

ArticleEye (London, England)2023

Six-month outcomes of infliximab and tocilizumab therapy in non-infectious retinal vasculitis.

Irmak Karaca, Gunay Uludag, Wataru Matsumiya, Jonathan Regenold, Christopher Or, Azadeh Mobasserian, Muhammad Sohail Halim, Moosa Zaidi, Sherin Lajevardi, Ami Dongchau and 2 more

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Human retinal endothelial cells express functional interleukin-6 receptor.Journal of ophthalmic inflammation and infection · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Irmak KaracaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0001-7927-0887
Gunay UludagSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Wataru MatsumiyaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Jonathan RegenoldSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Christopher OrSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Azadeh MobasserianSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Muhammad Sohail HalimSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Moosa ZaidiSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0003-1788-6306
Sherin LajevardiSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Ami DongchauSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Hashem GhorabaSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.ORCID 0000-0002-1145-4134
Quan Dong NguyenSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA. ndquan@stanford.edu.ORCID 0000-0002-6024-8441
Smith-Kettlewell Eye Research Institute · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

purposeTo evaluate the efficacy of infliximab (IFX, 5-10 mg/kg) (Group 1) and tocilizumab (TCZ, 4-8 mg/kg) (Group 2) infusions in non-infectious retinal vasculitis (RV) using Angiographic Scoring for the Uveitis Working Group fluorescein angiography (FA) scoring system.

methodsRecords of 14 patients (24 eyes) in Group 1 and 8 patients (11 eyes) in Group 2 were retrospectively evaluated to assess visual acuity (VA), anterior chamber cell and flare, vitreous haze, central subfield thickness (CST), and FA scoring at baseline and 6 months of follow-up. The measurements were employed to grade in each group.

resultsIn Group 1 and 2, respectively, there was no underlying disease in 9 (60%) and 3 (42.9%) patients. Three (42.9%) patients in Group 2 had juvenile idiopathic arthritis (JIA) as the most common identified cause. Mean improvement in VA (log MAR) and CST were 0.04 ± 0.14 and 40.3 ± 78.5 µm in Group 1; 0.04 ± 0.09 and 47.3 ± 82.3 µm in Group 2, respectively. Mean FA scores were significantly reduced from 12.4 ± 5.2 and 11.6 ± 4.4 at baseline to 6.4 ± 5.0 and 5.8 ± 3.9 at 6-month in Group 1 and 2, respectively. In Group 2, 9 eyes of 6 patients (75%) had the history of IFX use prior to TCZ initiation. There was no significant safety concern requiring treatment discontinuation during the follow-up in either group.

conclusionIFX and TCZ infusions showed statistically significant improvement of non-infectious RV as shown by ASUWOG FA Scoring System. TCZ, as well as IFX, appeared to be effective treatment options for non-infectious RV.

Indexed as

Retinal VasculitisUveitisAntibodies, Monoclonal, HumanizedFluorescein AngiographyHumansInfliximabRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedInfliximabtocilizumab

Identifiers

PMID36443499
PMCPMC10366079
OpenAlexW4310117833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.